NCT04867551已完成2 期
A Phase II Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Occurrence of adverse events
研究概览
简要总结
Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Japanese patients
- •Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease society brain bank clinical diagnostic criteria
- •Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr Scale
排除标准
- •Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease.
- •Patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain stimulation etc.) for PD, or patients for whom surgical treatment is scheduled during the study
- •Patients with a complication of obvious dementia, or patients with Mini-Mental State Examination (MMSE) score < 24 points
研究组 & 干预措施
KDT-3594
Experimental
干预措施: KDT-3594 (Drug)
结局指标
主要结局
Occurrence of adverse events
时间窗: 8 weeks
The numbers of events and subjects, the incidence regarding adverse events.
Plasma concentrations of KDT-3594 and its metabolites
时间窗: 8 weeks
Plasma concentrations of KDT-3594 and its metabolites during treatment period.
次要结局
- Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.Parkinson DiseaseNCT03845387Kissei Pharmaceutical Co., Ltd.74
已完成
2 期
A clinical study of KDT-3594 in Japanese patients with early Parkinson's disease.Parkinson's diseaseJPRN-jRCT2031210089Shimizu Yoshitaka6
已完成
2 期
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's DiseaseParkinson DiseaseNCT06722729Kissei Pharmaceutical Co., Ltd.178
已完成
1 期
Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseParkinson DiseaseNCT03068481Kissei Pharmaceutical Co., Ltd.36
已完成
1 期
A phase I clinical study of KSP-0243Healthy ConditionJPRN-jRCT2071200087Shimizu Yoshitaka144